However, the study, released Tuesday, found that the vaccine from U.S. pharmaceutical giant Pfizer and German partner BioNTech provided just 33 percent protection against infection, much less than the level for other variants detected in the country. At the same time, the vaccine provided 70 percent protection in fully vaccinated individuals against severe complications that would require a patient to be hospitalized, the study found, calling that “very good protection.”

Source link